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Maturational Changes In Myosin Light Chain Kinase Activity In Ovine Carotids
by
Elisha Raju Injeti
Doctor of Philosophy, Graduate Program in Pharmacology
Loma Linda University, September 2008
Dr. William J. Pearce, Chairperson

Vascular reactivity changes dramatically during postnatal maturation due in large
part to developmental changes in myofilament calcium sensitivity. Recent findings
suggest that reactivity of the thick filament component of calcium sensitivity is
upregulated in fetal compared to adult arteries. In light of these findings, the present
study tests the hypothesis that upregulation of fetal thick filament reactivity is due to
upregulation of myosin light chain kinase (MLCK) activity. To test this hypothesis,
MLCK abundance and its activity is measured in intact arteries. The results indicate that
MLCK abundance is 6.03 ± 0.96 fold greater in adult than in fetal arteries. Total MLCK
activity (%MLC phosphorylated/sec) estimated as the rate of phosphorylation of myosin
light chain in intact arteries was greater in fetal (7.39 ± 0.53) than in adult (6.56 ± 0.29)
arteries. When total MLCK activity was nonnalized relative to MLCK & MLC
abundance to estimate the apparent specific activity of MLCK (ng MLC
phosphorylation/sec/ng MLCK), these estimates were dramatically greater in fetal (1.52 ±
1.11) than in adult (0.26 ±0.01) arteries.
Further, to test if these differences are due to differences in fractional activation of
the enzyme, maximum velocity (Vmax) of MLCK was estimated in artery homogenates.

x

The results indicate that V max (ng MLC phosphorylated/sec) is significantly greater in
fetal (163 ± 11) compared to adult (130± 9) arteries. When fractional activation was
calculated the results showed about 4.9 ± 0.3 fold greater activation of MLCK in fetal
compared to adult arteries.
Together, these results support the hypothesis that upregulation of fetal thick
filament reactivity is due to upregulation of MLCK activity. These studies were the first
to offer a quantitative assessment of age related differences in MLCK activity in intact
arteries and indicate the relative extents to which changes in MLCK abundance, activity
and fractional activation contribute to these differences. From a clinical science
perspective, these studies help in understanding the mechanisms involved in adaptation of
fetal vascular system for postnatal life so that, new strategies of pharmacological
management of NICU neonates with cerebrovascular and cardiovascular instabilities can
be developed.
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CHAPTER 1

Introduction
A common feature of many infants in Neonatal Intensive Care facilities is
cardiovascular instability. Systematic investigation of this feature has revealed that
regulation of vascular contractility is markedly different in immature than in mature
arteries. These differences involve numerous mechanisms related to regulation of
cytosolic calcium concentrations, but recent studies have also suggested that contractile
proteins are regulated very differently in mature and immature arteries. The exact
mechanisms responsible for these age-related differences, however, remain unknown,
despite their obvious clinical relevance and importance.
From the simplest perspective, the mechanisms regulating contractile protein
function can be categorized into two main families. The first includes those that
determine the dynamics and extent of myosin phosphorylation in response to changes in
cytosolic calcium, and thereby regulate thick-filament contractile function. The second
includes those mechanisms that control the ability of actin filaments to bind to
phosphorylated myosin, and thereby regulate thin-filament function. For both thick and
thin-filament regulation, many of the signal transduction mechanisms involved remain
unclear or controversial. However, most studies of thick filament regulation have thus far
focused on regulation of MLCP and relatively little has been elucidated regarding the
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importance of regulation of MLCK in overall regulation of myofilament calcium
sensitivity. Almost nothing is known of thick filament regulation in immature arteries.
In light of recent observations that the regulation of myofilament calcium
sensitivity is markedly different in mature and immature arteries, and also that the
significance of thick filament regulation changes with maturation, this study proposes to
test the general hypothesis that age-related differences in myofilament calcium
sensitivity involve upregulation ofMLCK activity in fetal compared to adult arteries.
This main hypothesis, in turn, gives rise to at least three main corollaries:
Corollary Hypothesis #1: Age-related differences in myofilament calcium
sensitivity involve up-regulation of MLCK abundance in immature arteries;
Corollary Hypothesis #2: Age-related differences in myofilament calcium
sensitivity involve increased MLCK intrinsic activity in immature arteries;
Corollary Hypothesis #3: Age-related differences in myofilament calcium
sensitivity involve increases in fractional activation of MLCK in immature arteries.
In order to test our main hypothesis and its corollaries, we will conduct
experiments designed to address the following specific aims:
Specific Aim # 1: Measure MLCK and MLC abundance in fetal and adult
common carotid arteries via quantitative Western blots.
Specific Aim #2: Measure the velocity of myosin light chain phosphorylation in
intact tissue and normalize to abundance of MLCK and MLC to estimate the in-situ
MLCK velocity.
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Specific Aim # 3: Measure the maximum velocity of myosin light chain
phosphorylation in tissue homogenates using purified chicken gizzard MLC as a substrate
to estimate the Vmax and Km of MLCK.
Specific Aim # 4: Measure the fractional activation of MLCK in intact tissue by
dividing the in-situ MLCK velocity with Vmax values of MLCK from artery homogenates.
Given the relatively large amount of tissue required for multiple reliable
measurements of MLC phosphorylation from a single artery sample from a single animal,
we will perform these experiments using common carotid artery segments from term fetal
and non-pregnant adult sheep.

Background
The contractile proteins like actin and myosin are most commonly present in
almost all types of eucaryotic cells. These proteins are involved in regulation of important
cellular processes like endothelial cell retraction, platelet aggregation and contraction,
fibroblast contraction, secretion, receptor capping, nerve growth cone motility and
muscle contraction (20, 40, 73, 76). Of all these functions, their role in contractile activity
of muscle cells like cardiac, skeletal and smooth muscles is well established and
documented in the literature (78). The contractile response of all these muscle types is
mainly due to the interaction of myosin heads with the thin filaments formed by actin
polymers. More than 100 years ago, Sydney Ringer has shown that this interaction
depends on influx of extracellular calcium into muscle cells (62, 63). Numerous studies
that followed established not only the central role of calcium in regulating contractile
function of cardiac, skeletal and smooth muscles but also elucidated the differences in
protein machinery involved in each muscle type.
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Especially in smooth muscles, three theories have been proposed to explain the
mechanisms regulating contractile proteins. They are (i) phosphorylation theory (ii)
leiotonin theory (iii) troponin theory (51). Among these, phosphorylation theory is the
most dominant one, which proposes that regulation of contractile activity operates via the
phosphorylation and dephosphorylation of the MLC20 present on myosin molecule (5, 10,
23, 27, 35, 52, 69, 71). The major opposition to this theory is from Ebashi and co-workers
who proposed that regulation of smooth muscle contraction takes place through
interaction with proteins called leiotonin A & C and does not require reversible
phosphorylation of myosin (14, 47-49). Both these theories were preceded by troponin
theory, which claimed that a troponin C-like molecule exists in smooth muscles that
regulate contractile function (9, 15, 16, 29). However, two important findings lead to the
rejection of troponin theory. Firstly, it was shown that troponin C is actually calmodulin,
which is present in a wide variety of cells apart from smooth muscle cells (24, 25, 29).
Secondly, the contradictory functions of troponin as an inhibitor in skeletal muscle
contraction and activator in smooth muscle contraction lead to its failure. On the other
hand, further studies by Ebashi and co-workers, led to the conclusion that leiotonin is
infact myosin light chain kinase and that it also exhibits a non-kinase related activity
along with kinase activity (17). Given these findings, phosphorylation theory became a
widely accepted viable theory to explain the regulation of smooth muscle contractility.
These developments led to the emergence of myosin light chain kinase as a crucial
enzyme that phosphorylates myosin light chain and is both necessary and sufficient for
smooth muscle contraction. This pivotal role of myosin light chain kinase is further
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confirmed by a direct demonstration at the level of single smooth muscle cells as well as
whole animal studies involving MLCK knock out mice (39, 74).

Myosin Light Chain Kinase
Myosin light chain kinase (MLCK) is a calcium/calmodulin dependent protein
kinase that phosphorylates serine-19 residue on the N-terminal of the MLC20. Due to its
high specificity for MLC20, it is known as a dedicated protein kinase. It is ubiquitously
distributed in smooth muscle, skeletal muscle, and non-muscle cells. Smooth muscle
MLCK is product of a single gene that is different from skeletal muscle MLCK and has
two splice variant products ranging from 130-150 kDa (short MLCK) and 208-214 kDa
(long MLCK) (72). Studies have shown that long MLCK is expressed in non muscle cells
like endothelium while the short MLCK is expressed in smooth muscle cells (59, 83).
Colocalization studies also suggest that these MLCK isoforms have different distribution
profiles implicating different physiological functions in both non-muscle cells and
smooth muscle cells (8, 61). This was confirmed by studies conducted on knockout mice
that these isoforms have some non-redundant functions (59, 83).
MLCK isoform expression has also been studied from the perspective of
developmental biology. Expression of long MLCK isoform during chicken embrogenesis
is shown by RT-PCR methods. Direct sequencing of the RT-PCR product from
embryonic tissue RNA revealed long MLCK isoform. In addition, cultured embryonic
gizzard and vascular smooth muscle cells expressed the short MLCK isoform, albeit at
lower levels than in vivo tissues (18). In other studies Gallagher and co-workers have
found that long MLCK isofonn is most abundant during early development and gradually
declines at birth. In contrast, expression of short MLCK isoform is relatively low early
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during development and increases to become the predominant MLCK detected in all
adult smooth and non-muscle tissues (19, 60). Although these MLCK isoforms have
distinct expression and localization patterns, they have identical catalytic domains (30).
Structural analysis of MLCK molecule reveals that it contains three regulatory
domains: (i) actin binding domain; (ii) catalytic domain along with regulatory domain
(iii) myosin binding domain (Figure 1)(33). The actin binding domain is present on the
N-terminal side of the molecule and shows high affinity binding towards actin filaments
most likely due to its DFRXXL motifs (68). Short MLCK has three repeats of DFRXXL
motif and long MLCK has 5 such repeats along with 6 Ig-like modules. DFRXXL motifs
are necessary for short MLCK isoform to bind to actin-containing filaments while in long
MLCK isoform they confer high affinity binding to stress fibers in cells (67). The kinase
activity for phosphorylation is localized at the catalytic domain of MLCK. This domain is
repressed by substrate inhibitory domain during non-stimulatory conditions. In the
presence of calcium, calmodulin undergoes a conformational change that exposes two
hydrophobic pockets, one in each globular lobe that is important for binding to MLCK.
Upon binding calmodulin, MLCK undergoes a conformational change that derepresses
the catalytic site, allows substrate access and light chain phosphorylation (45, 46). The Cterminal domain of MLCK has been shown to bind to unphosphorylated smooth muscle
myosin. This domain is also independently expressed as a protein called telokin. When
the functional significance of the C-tenninal domain (telokin) and the molecular
morphology of MLCK was studied, it was found that telokin inhibited phosphorylation of
myosin by MLCK (70). These results indicate that MLCK binds to the head-tail junction
of unphosphorylated myosin through its C-tenninal domain, where MLC20 can be
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promptly phosphorylated through its catalytic domain following the calcium/calmodulindependent activation (58).

Actin

Catalytic
Domain

Binding
Domain

Myosin

Binding
Domain

N-Termina!

C-Terminal
Structure of MICK

Figure 1. Structure of MLCK

MLCK plays a prominent role in regulation of actomyosin-dependent contraction
in both smooth and non-muscle cells where myosin II is activated by myosin light chain
phosphorylation. This phosphorylation results in a variety of cellular responses including
cytoskeletal remodeling by stress fibers, fibroblast contraction, angiogenesis, changes in
endothelial permeability, normal and cancer cell migration, asthma, hypertension, and
atherosclerosis (72). Especially in smooth muscle, calcium-dependent MLCK activation
results in MLC20 phosphorylation and force development. The ability of MLC20
phosphorylation to initiate contraction has been demonstrated by treatment of both intact
cells and skinned fibers with proteolytically activated MLCK in absence of elevated
calcium (38, 39). MLCK activity undergoes dramatic changes depending on the
physiological conditions like pregnancy. For example, harmones like progesterone,
estrogen, gonadotrophin increases MLCK activity by atleast 2 fold (57). In contrast,
relaxin inhibits uterine contractility by decreasing MLCK activity (84)
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The activity of MLCK is regulated by phosphorylation mediated by a number of
different kinases. MLCK phosphorylation at the C-terminus of the calmodulin binding
sequence increases KcaM and decreases MLCK activity. Multiple kinases including PKA
(1, 12), PKG (56), PKC (36), and CaM kinase-II (28, 77) can phosphorylate MLCK.
However, only CaM kinase-II mediated phosphorylation was found to be physiologically
significant (75). Another important mechanism for regulating MLCK activity is through
telokin, a 17 kD acidic protein that is expressed exclusively in smooth muscle tissues and
cells (31, 37). It is expressed at high levels in smooth muscles such as intestinal and
urinary smooth muscle but only at very low levels in vascular smooth muscle (11,31).
Other studies suggest that telokin inhibits MLCK activity in broken cell preparations (58,
66). Among these studies very few have looked at age related changes in MLCK activity
and virtually none of them have studied the role of MLCK activity in age related changes
in myofilament calcium sensitivity.

Myofilament Calcium Sensitivity
Myofilament calcium sensitivity is the increment in force generated for a given
increment in intracellular calcium concentration. This increment in force for a given
increment in intracellular calcium concentration is more pronounced when the arteries are
stimulated by pharmacomechanical methods (32, 33). Clinically, myofilament calcium
sensitivity plays a key role in contractile function of vascular smooth muscle during
hypertension, myometrium during parturition and in airway smooth muscle during
asthma (65). When myofilament calcium sensitivity following G-protein coupled receptor
stimulation was observed from a developmental perspective, it was found to be
significantly greater in immature than mature arteries (2, 3). Studies on regulation of
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myofilament calcium sensitivity have revealed that a number of factors such as rhokinase (26, 41), PKC (4, 33), caldesmon and calponin (50, 54, 79) play a key role in its
regulation. To organize all these different mechanisms that regulate myofilament calcium
sensitivity, they can be classified into two main families. The first includes those that
determine the relationship between intracellular calcium concentration and extent of
myosin light chain phosphorylation and thereby regulate thick filament contractile
function (53). These mechanisms can be collectively considered as mediators of thick
filament regulation. The second family includes those mechanisms that influence the
relations between the extent of myosin light chain phosphorylation and force generated
by the contractile proteins. These latter mechanisms can be collectively considered to be
the mediators of thin filament regulation. More recent studies have demonstrated that
both thick filament and thin filament regulation change with age, and that thick filament
regulation is upregulated in immature compared to mature arteries (64).
Thick filament regulation plays a key role in the initiation of smooth muscle
contraction. The extent of myosin light chain phosphorylation at any given moment is the
net effect of the activities of myosin light chain kinase and myosin light chain
phosphatase. Studies investigating thick filament regulation have focused much of their
attention on myosin light chain phosphatase (MLCP) activity and its regulation. MLCP is
a heterotrimeric protein with a regulatory subunit (MYPT1) and catalytic subunit (PPlc).
There are three general mechanisms that regulate MLCP activity by: (i) phosphorylating
MYPT1; (ii) dissociating MLCP structure; and (iii) inhibition of activity by CPI-17. All
these mechanisms involve specific kinases that increase MLC phosphorylation by
depressing MLCP activity. PKCe is a specific kinase that can phosphorylate MYPT1 and
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inhibit dephosphorylation of myosin light chain (80). Regarding dissociation of MLCP
structure, arachidonic acid has been reported to separate MYPT1 from PPlc and thereby
inhibit dephosphorylation of myosin light chain (22). Other studies have shown that
phosphorylation of MYPT1 subunit at Thr696 inhibits its activity (34, 41). Other kinases,
such as Zip-like kinase (44) and Zip kinase (55), are also likely to be involved in
phosphorylation at Thr696 even though their physiological relevance is unknown.
Regarding CPI-17 mediated inhibition of MLCP activity; the binding affinity of CPI-17
for PPlc is regulated by phosphorylation of CPI-17 at Thr38 by PKC. Phosphorylated
CPI-17 can bind to PPlc and inhibit its activity. Other kinases, such as Rho-kinase (42)
and Zip like kinase (44), can also phosphorylate CPI-17 at the same site. All these studies
indicate the complex pathways involved in regulation of MLCP.
In contrast to MLCP, relatively very few studies have focused on the role of
MLCK in regulating myofilament calcium sensitivity (21, 81). When the physiological
significance of MLCK phosphorylation during cycles of contraction and relaxation in
smooth muscles was investigated, it was found that MLCK phosphorylation and
dephosphorylation occurred at rates sufficient to modulate the Ca2+ sensitivity of myosin
light chain phosphorylation (85). These results indicate that MLCK is sensitive to small
increases in intracellular Ca2+ during the initiation of contraction and has an important
role in regulation of thick filament reactivity. Recent publications from our lab have
shown that myofilament calcium sensitivity of fetal arteries is upregulated compared to
adult arteries (64). Additional studies have further shown that thick filament regulation is
also upregulated in fetal compared to adult arteries (64). Because thick filament
regulation is a function of both MLCK and MLCP activities, these results suggest that
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either MLCK and/or MLCP activities are different in fetal and adult arteries. Even when
MLCP is completely inhibited by phosphatase inhibitors, age related differences in thick
filament regulation are still evident, however. This observation suggests the possibility
that MLCK activity may be involved in age-related differences in myofilament calcium
sensitivity. Other studies of MLCK activity have shown that it plays an important role in
maintaining contractility in saphenous vein (43), pulmonary arteries (6, 7), and
myometrium (84). Given this background, the core hypothesis of this project is that agerelated differences in myofilament calcium sensitivity involve up-regulation of MLCK
activity in fetal compared to adult arteries. A systematic investigation of this hypothesis
will illuminate the contribution of MLCK activity to postnatal maturation of vascular
contractile function.

Significance
The proposed studies are important from both basic science and clinical science
perspectives. From the basic science point of view, the proposed experiments will be the
first to offer a quantitative and comprehensive assessment of age-related differences in
MLCK abundance and intrinsic activity. Another highly unique aspect of these studies is
that these measurements will utilize a custom-designed rapid-freeze apparatus that can
electrically stimulate the tissue and simultaneously freeze it at very short intervals of
time. These studies will be the first to compare age-related differences in MLCK
activities under both in-situ and in-vitro conditions. These novel assessments will give
the most physiologically relevant estimates of MLCK activity available to date. Because
it is clear that maturation alters thick filament regulation, the proposed studies, regardless
of outcome, should clearly indicate the relative extents to which changes in MLCK
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abundance, intrinsic activity, and fractional activation contribute to the age-dependent
differences in myofilament calcium sensitivity.
From a clinical science perspective, the proposed experiments will help in
understanding the mechanisms involved in adaptation of the fetal cardiovascular system
for postnatal life. At birth, arterial blood pressure, heart rate, cardiac output increases and
vascular resistance must rapidly adjust to these changes. Failure to make these
adjustments contributes to central and peripheral vascular disorders including neonatal
stroke (86), intracranial hemorrhage (82) and respiratory failure (13). Although the
reasons for these disorders are attributed to functional immaturity of cardiovascular
system, the proposed studies will explore the role of MLCK and should identify a
possible target for new strategies of pharmacological management of NICU neonates
with cerebrovascular and cardiovascular instabilities.
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Abstract
Postnatal decreases in vascular reactivity involve decreases in the thick filament
component of myofilament calcium sensitivity, which is measured as the relation
between cytosolic calcium concentration and the extent of myosin light chain (MLC20)
phosphorylation. The present study tests the hypothesis that downregulation of thick
filament reactivity is due to downregulation of myosin light chain kinase (MLCK)
activity, in adult compared to fetal arteries. Total MLCK activity, estimated as % MLC20
phosphorylated/sec in intact arteries during optimal inhibition of myosin light chain
phosphatase activity, was significantly less in adult (6.56 ± 0.29%) than in fetal (7.39 ±
0.53%) preparations. The abundances of MLC20 did not differ significantly in adult and
fetal arteries and averaged 1.42 ± 0.21 and 1.21 ± 0.37 pg/mg wet weight, respectively.
Correction of MLCK activities for differences in MLC20 abundance yielded values of
93.2 ±4.1 and 89.4 ± 6.4 ng MLC20 phosphorylated/sec/mg wet weight, respectively;
again, these values were not significantly different. MLCK abundance, however, varied
significantly with age and averaged 354.7 ± 25.6 and 58.7 ± 4.24 ng MLCK/mg wet
weight in adult and fetal arteries, respectively. Normalization of MLCK activities for
MLCK abundance yielded values (in ng MLC20 phosphorylated/sec/ng MLCK) that were
significantly less in adult (0.26 ± 0.01) than in fetal (1.52 ± 0.11) arteries. Together, these
results emphasize the importance of nonnalization of MLCK activities relative to MLC20
and MLCK abundances, and indicate that downregulation of apparent specific activity of
MLCK contributes significantly to downregulation of thick-filament reactivity in adult
compared to fetal ovine carotid arteries.
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Key words
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Introduction
Cardiovascular instability is a common feature of many infants in neonatal intensive
care facilities. Systematic investigation of this symptomology has revealed that regulation
of vascular contractility varies markedly between immature and mature arteries (5, 42).
Previous studies from our lab have shown that these age-related differences in
contractility involve major differences in intracellular calcium regulation. For equivalent
contractile tensions, immature carotid arteries require greater calcium uptake than mature
arteries, indicating a greater contractile dependence of immature arteries on extracellular
calcium (54). Other studies have further demonstrated that the relative size of
intracellular calcium stores change significantly during postnatal maturation (39). Despite
these important differences in calcium regulation, however, intracellular calcium
dynamics alone cannot completely explain the age-related differences in regulation of
vascular contractility. As shown in multiple recent studies, differences in regulation of
myofilament calcium sensitivity also contribute heavily to age-related changes in
vascular contractility (1,2).
By definition, myofilament calcium sensitivity is the increment in force generated
for a given increment in intracellular calcium concentration (48). Changes in
myofilament calcium sensitivity influence contractile function of vascular smooth muscle
during hypertension, in myometrium during parturition, and in airway smooth muscle
during asthma (47). Regulation of calcium sensitivity, in turn, is mediated through both
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thick filament regulatory pathways that establish the relation between intracellular
calcium concentration and myosin light chain phosphorylation, and thin filament
regulatory pathways that determine the relations between myosin light chain
phosphorylation and contractile force (38, 46). When examined from a developmental
perspective, G-protein coupled receptor stimulation has enhanced myofilament calcium
sensitivity to a much greater extent in immature than in mature cerebral arteries (2, 3).
Additional detailed studies have further revealed that the extent of myosin light chain
phosphorylation was greater for a given increment of cytosolic calcium in fetal than in
adult arteries, suggesting that thick filament regulation was upregulated in the immature
arteries (46). In contrast, myosin light chain kinase (MLCK) and myosin light chain
phosphatase (MLCP), which are the two main enzymes that dominate thick filament
reactivity, were less abundant in fetal than in adult arteries (46). Together, these findings
indicate that thick filament reactivity, and the enzymes that govern it, change
dramatically during postnatal maturation
To date, most studies of stimulation-induced changes in myosin light-chain
phosphorylation have focused on regulation of MLCP (48). Whereas this enzyme is
clearly regulated by numerous pathways, MLCK also plays a critically important role in
regulation of contraction in both smooth muscle and non-muscle cells. Through a
sequence of reactions that are particularly prominent in smooth muscle, calciumdependent MLCK activation results in MLC20 phosphorylation, activation of myosin II
actomyosin ATPase activity, initiation of cross-bridge cycling and force development. As
the main high-speed kinase responsible for phosphorylating regulatory myosin light
chain, MLCK is both necessary and sufficient to initiate smooth muscle contraction (20).
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Correspondingly, MLCK-dependent regulation of contractile function has been carefully
detailed under both physiological and pathophysiological conditions in many
preparations including saphenous vein (31), pulmonary arteries (6) and myometrium (53).
In light of this rich background, we designed the present studies to explore the hypothesis
that age-related differences in myofilament calcium sensitivity involve up-regulation of
MLCK activity in fetal compared to adult arteries. To maximize relevance to contractile
function, the experimental approach relied on rapid measurements of MLC20
phosphorylation in whole arteries. Owing to the extensive literature documenting changes
in ovine carotid contractility during postnatal maturation, all experiments employed this
model.

Materials and Methods

General Preparation
Common carotid arteries were harvested from young adult sheep (18-24 months old)
following i.v. injection of 100 mg/kg pentobarbital. Fetal carotid arteries were collected
after delivery of each fetus (-140 days gestation) from its pregnant ewe by a midline
vertical laparotomy, after which the fetus was rapidly killed by cardiac excision. The
arteries were cleaned of extraneous connective and adipose tissue and the endothelium
was removed by passing a roughened needle through the lumen, as described in multiple
previous studies (40). All procedures used in these studies were approved by the Animal
Research Committee of Loma Linda University and adhered to all policies and practices
outlined in the National Institutes of Health Guide for the Care and Use of Laboratory
Animals
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Determination of MLCK Abundance
Common carotid arteries from fetal and adult sheep were pulverized in liquid
nitrogen using a custom made stainless steel mortar and pestle and then homogenized
with glass-on-glass in 4 volumes of buffer containing 0.5 M NaCl, 50 mM Tris HC1 at pH
7.5, 10 mM MgCC, 1 mM EDTA, 1 mM EGTA, 0.1 mM phenylmethylsulfonyl fluoride,
0.5% Protease Inhibitor Cocktail (Sigma, P8340), and 0.1% betamercaptoethanol.
Following centrifugation at 15,000 rpm for 15 minutes at 4° C, the supernatant was
assayed for total protein content (Biorad, #500-0006). For each determination, 20 pg of
total protein were loaded on a 15-lane, 8% SDS-PAGE gel, and run at 15 mA for 90
minutes and then transferred onto nitrocellulose membrane. The membrane was blocked
overnight at 4° C with 5% non-fat dry milk in 20 mM Tris HC1 at pH 7.5, 500 mM NaCl
and 0.1% Tween-20 and then probed with mouse anti-MLCK primary antibody (Sigma,
M7905) at 1:7,000 dilution for 2 hours. Primary antibody-antigen complexes were
detected with a goat anti-mouse secondary antibody (Pierce, #1858413), and visualized
using direct photon capture with a CCD camera (Alphalnnotech, Chemi-Imager).
Adjacent lanes of each gel were loaded with 6 different quantities of a reference MLCK
standard prepared from ovine carotids to enable relative quantification. The reference
MLCK standard was further calibrated for absolute quantification with purified MLCK
from chicken gizzard, which was a gift from Dr. Christine R. Cremo.

Determination of MLC20 Abundance
Common carotid arteries from fetal and adult sheep were pulverized in liquid
nitrogen using a custom made stainless steel mortar and pestle. The pulverized tissue was
extracted for 2 hours using a buffer containing 8 M Urea, 20 mM Tris, 23 mM Glycine,
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10 mM EGTA, 10 mM DTT, 5 mM NaF, 10% Glycerol at pH 8.6 with a tissue to buffer
ratio of 1:300. After two hours of extraction on an orbital shaker, the homogenates were
centrifuged at 12,000G for 20 minutes after which the supemates were removed and the
pellets were extracted a second time. The supemates were combined and their absolute
content of MLC20 was assayed by separating 10 pi sample aliquots on 15% SDS gels at a
constant voltage (100 V) for 2 hours. Varying known quantities of purified MLC20 from
chicken gizzard was run on multiple adjacent lanes to enable construction of a standard
curve. The purified MLC20 used as an absolute reference was prepared from chicken
gizzard and was a gift from Dr. Christine R. Cremo. The gels were transferred onto
nitrocellulose membranes at constant current (50 mA) for 3 hours after which
immunoblotting was performed as previously described (46). Briefly, membranes were
blocked with 5% milk in TBS (20 mM Tris HC1, 500 mM NaCl, pH 7.5) for 90 minutes.
The blocked membranes were incubated in primary anti-MLC antibody (Sigma, M4401)
at 1:300 dilution with 5% milk in Tween-TBS for 3 hours, followed by incubation for 90
minutes at a 1:1000 dilution of a goat anti-mouse secondary antibody (Pierce, #1858413)
conjugated with horse radish peroxidase. All washes were carried out with Tween-TBS
containing 5% milk. Antibody-antigen complexes were detected by chemiluminescence
using a mixture of equal volumes of enhanced luminol reagent and oxidizing reagent
(Pierce, #34096). Membranes were then scanned to determine the integrated optical
density values of MLC20 bands using direct photon capture (Chemi-Imager, AlphaInnotech), and these values were converted into MLC20 masses using the standard curve
on each membrane. To enable comparisons between age groups, the values of MLC20
mass were expressed as pg MLC20 per mg wet weight of tissue.
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Determination of Optimal Length for Contractile Response in Intact Carotid Arteries
Given that maximum MLCK activity occurs during maximal rates of contraction,
which in turn develop only at optimal artery stretch, the optimal stretch ratios for carotid
arteries from each age group were determined. Common carotid arteries obtained from
adult sheep and near term fetuses were cleaned of adhering tissues, cut into 2-mm
lengths, and placed in Krebs solution containing 122 mM NaCl, 25.6 mM NaHCOs, 5.56
mM dextrose, 5.17 mM KC1, 2.49 mM MgSCL, 1.60 mM CaCl2, 0.114 mM ascorbic acid
and 0.027 mM EGTA that was continuously bubbled with 95% O2 and 5% CO2. Each
segment was mounted within a warmed tissue bath on wires and suspended between a
force transducer and a post attached to a micrometer. After equilibration in Krebs
solution at 38.5 °C (normal ovine core temperature) for at least 30 minutes, micrometer
readings were obtained at 0.05 g tension, which enabled measurements of unstressed
diameter (Do) for each segment. The artery segments were then stretched in regular
multiples of unstressed baseline diameter to yield stretch ratios (D/Dq) ranging from 1.0
to 3.0 times unstressed diameter. At each stretch ratio, the arteries were briefly contracted
with 122 mM K+ until a peak response was obtained, after which the segments were
returned to normal Krebs and equilibrated for 30 minutes before the next increment in
stretch was applied. When contractile responses to K+ had been recorded at all stretch
ratios, active tensions were calculated and plotted against their corresponding stretch
ratios for both fetal and adult arteries, as previously described (42).

Determination of Optimal Concentration of Myosin light Chain Phosphatase Inhibitors
Both adult and fetal carotid artery segments were cleaned, wire-mounted and then
stretched to their optimal length. Following equilibration and initial contraction with 122
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mM K+ Krebs, the arteries were washed three times with Na+ Krebs buffer and
incubated with four different concentrations (0, 10, 30, and 100 nM) of calyculin-A for
an hour. Next, the segments were instantly frozen after exactly 9 seconds of contraction
with 122 mM K+ using an acetone/TCA freezing solution held on dry ice at -70 °C.
Arteries were similarly frozen following incubation in four different concentrations (0, 3,
10, and 30 jiiL/mL) of Phosphatase Inhibitor Cocktail (Sigma, P2850). Frozen segments
were extracted and analyzed on 10% urea glycerol gels to quantify the extent of myosin
light chain phosphorylation as previously described (46). Briefly, the gels were loaded
with equal amounts of total protein and run for two and half hours at constant voltage
(200V) and then transferred onto nitrocellulose membrane at constant current (50 mA)
for 3 hours. Membranes were then blocked as described in the section titled
“Determination of MLC20 abundance” and analyzed for MLC20 phosphorylation.

Determination of Concentration and Time Dependent Effects of ML-7 on MLCK
Activity
Artery segments from both fetal and adult animals were prepared as described in the
previous section. Following equilibration and contraction with 122 mM K+ Krebs, the
arteries were washed three times with Na+ Krebs and incubated with five different
concentrations (0, 10, 30, 100, and 300 nM) of ML-7 for 30 minutes followed by
incubation with Phosphatase Inhibitor Cocktail (10 pL/mL) for an hour. Next, the
segments were instantly frozen after exactly 9 seconds of contraction with 122 mM K+
using an acetone/TCA buffer on dry ice at -70 °C. Frozen segments were extracted and
analyzed on urea gels to quantify the extent of myosin light chain phosphorylation as
previously described (46). In a companion set of experiments, the time course of MLC20
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phosphorylation in response to potassium contraction was determined in the presence and
absence of the optimal concentration of ML-7 to verify the efficacy of inhibition by ML7. Arteries were frozen at exactly 0, 3, 6, and 9 seconds after contraction and analyzed for
MLC20 phosphorylation via urea gels.

Comparison of Chemical and Electrical Methods of MLCK Activation
To enable measurement of MLCK activity in intact tissues, we fabricated a rapid
freeze apparatus following a design described by Maass-Moreno et al. (32). Our
apparatus included a specialized low volume tissue cuvette (1.5 ml) equipped with large
surface area platinum foil electrodes arranged to deliver high current density via electrical
field stimulation (EPS). Current magnitude was measured directly via oscilloscope as a
voltage-drop across a known resistance. Artery segments were mounted in the cuvette
between a stationary hook and a force transducer that continuously monitored contractile
force. The force transducer was mounted on a digital micrometer that enabled precise
positioning (±1 pm) and stretch of the artery segments. The time of freezing was
precisely controlled using a computer-based timing circuit that operated high-speed
solenoid valves and enabled very rapid (<200 msec) exchange of Krebs buffer for -70 °C
acetone/TCA buffer. Arteries were stimulated with 100 mA of current at 60 Hz and 4 ms
duration and simultaneously frozen at exactly 0, 2, 4 & 8 seconds and analyzed for
MLC20 phosphorylation. Comparison measurements were made, by stimulating with 122
mM K+ or 25 pM 5HT with freeze times of 0, 4, 8, & 12 seconds and subsequent analysis
for MLC20 phosphorylation.
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Determination of current -contractile responses in intact carotid arteries:
Both fetal and adult arteries were mounted in the rapid freeze apparatus, equilibrated
after which contractile responses to 122 K+ Krebs were determined. The segments were
then rinsed, equilibrated in normal sodium Krebs buffer for one hour, then stimulated
with graded EPS currents of 40, 50, 55, 60, 70, 75, 80, 90 & 100 mA. Contractile
responses to EPS were normalized relative to the responses to K+-Krebs.

Determination of MLCK Activity in Intact Carotid Arteries
To measure MLCK activity, in-situ, common carotid arteries were prepared as
described in section titled “Determination optimal length for contractile response in
intact carotid arteries” and then mounted in the rapid freeze apparatus. Following
equilibration and contraction with 122 mM K+ Krebs, the arteries were washed and
incubated in 10 pL/mL of PIC for an hour. Next, EPS (90 mA @ 60 Elz) was applied and
segments were frozen at 0, 1, 2, and 3 seconds of stimulation. Frozen segments were
extracted and analyzed on urea gels to quantify the extent of myosin light chain
phosphorylation as described in section titled “Determination of MLC20 abundances
The slope of this relation, which was an estimate of the rate of phosphorylation of myosin
light chain, was calculated as a measure of MLCK activity. The apparent specific activity
of MLCK was estimated by dividing the rate of MLC20 phosphorylation by absolute
MLCK abundance.

Calculations and Statistics
Standard curves relating protein mass to optical density in Western blots, or
stimulation current to contractile response, were fit to the logistic equation using least -
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squares error minimization routines, and sample protein masses were calculated directly
using the inverse function of the best fit standard curve. The abundances of MLCK and
MLC20 were calibrated relative to MLCK and MLC20 purified from chicken gizzard and
were expressed in units of ng MLCK. Values of %MLC2o phosphorylation values were
calculated as the unphosphorylated mass divided by the sum of phosphorylated and
unphosphorylated masses as previously described (46). Relations between %MLC2o
phosphorylation and inhibitor concentrations or time were fit to rectangular hyperbolae,
also using least -squares error minimization routines. Throughout the text, all values
indicate the mean ±the standard error for the number of animals indicated; values of N
refer to the numbers of animals and not the numbers of segments or experiments unless
indicated otherwise. Unpaired comparisions between two variables were performed using
Behren’s-Fisher comparisons with pooled variance. All data sets were verified to be
normally distributed using SPSS vl6 software. In all cases, statistical significance implies
P<0.05.

Results
A total of 207 and 245 carotid segments were taken for study from 29 ovine fetuses
and 35 adult sheep respectively.

Effect of Postnatal Maturation on MLCK and MLC20 Abundances
Estimates of MLCK abundance in fetal tissue averaged 58.7 ± 4.2 ng MLCK/mg
tissue wet weight. These values were significantly less than average MLCK in adult
tissue (354.7 ± 25.6 ng MLCK/mg tissue wet weight). MLCK abundance was 6.03 ± 0.96
fold greater in adult than in fetal arteries (Figure 1). None of the gels examined exhibited
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more than a single immunoreactive band for MLCK, and no evidence of a low molecular
weight immunopositive product of MLCK (telokin) was observed in either age group.
MLC20 abundance in fetal arteries averaged (1.21 ± 0.37 pg/mg wet weight) whereas
abundance in adult arteries averaged (1.42 ± 0.21 pg/mg wet weight). These results
indicate that MLC20 abundances, unlike MLCK abundances, did not vary significantly
with age.

Length-Tension Relations in Ovine Carotid Arteries
As shown in Figure 2, the stretch ratio (D/Dq) associated with the maximum
contractile response was significantly greater in adult (2.58 ± 0.07) than in fetal (1.70 ±
0.06) arteries. These results agree with our previous findings that fetal and adult arteries
have different optimum lengths, which are probably attributable to age-related
differences in artery wall thickness and compliance (42)

Optimum Concentration of Myosin Light Chain Phosphatase Inhibitors
In both fetal and adult arteries, 30 nM calyculin-A maximally increased the %MLC2o
phosphorylation associated with contraction (Figure 3, upper panel). The maximum
%MLC2o phosphorylation averaged 47.9 ± 3.40% in fetal, and 27.6 ± 1.46% in adult,
arteries. Maximal increases in %MLC2o phosphorylation produced by Phosphatase
Inhibitor Cocktail were observed at 10 pL/mL in both age groups (Figure 3, lower
panel), and maximum %MLC2o phosphorylation averaged 50.9 ± 2.57% in fetal, and
55.6 ± 3.10% in adult arteries. Because PIC at 10 pL/mL yielded greater maximal
%MLC2o phosphorylation than calyculin-A, all further studies used 10 pL/mL PIC to
inhibit MLCP. Because PIC was designed to inhibit more types of phosphatase than
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calyculin-A (28), and the difference between the maximum %MLC2o produced by PIC
and calyculin A was much greater for adult than fetal arteries, the results also suggest that
adult arteries may express a different combination of phosphatases than expressed in fetal
arteries.

Concentration and Time Dependent Effects of ML-7 on MLCK Activity
ML-7 at a concentration of 100 pM maximally inhibited both fetal and adult MLCK
activity (Figure 4, upper panel). ML-7 also exhibited a dose-dependent decrease in
contractile response of the artery segments in response to 122 mM K+ (data not shown).
Using this optimal concentration of ML-7, its effects on the time courses of MLC20
phosphorylation were then examined. As shown in Figure 4 (lower panel), 100 pM of
ML-7 completely inhibited any time dependent increase in MLC20 phosphorylation or
contraction (data not shown) following 122 mM K+ stimulation. These results indicate
that MLCK is most probably the only kinase involved in MLC20 phosphorylation during
the first 9 seconds of contraction. The results do not exclude MLC20 phosphorylation by
other kinases at later time points, but largely rule out the participation of non-MLCK
phosphorylation during the initial contraction.

Comparison of Chemical and Electrical Methods of MLCK Activation
Electrical field stimulation yielded peak phosphorylation values at 2 seconds
followed by a rapid decline. In contrast, contraction with 122 mM K+ and 25 pM 5-HT
exhibited peak values of MLC20 phosphorylation after 8 seconds of stimulation (Figure
5, upper panel). The 5-HT and K+ results agreed with our previous measurements, and
suggested that MLC20 phosphorylation was very fast and was probably limited by the rate
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of diffusion of the agonist through the artery wall in large arteries. Correspondingly, the
data suggest that electrical field stimulation was the optimal approach for activating
MLCK, in situ

Current-Tension Relations in Ovine Carotid Arteries
To assure maximal activation of MLCK, the contractile responses produced by
graded currents of electrical field stimulation in both fetal and adult arteries were
examined. As shown in Figure 5 (lower panel), 90 mA of current at 60 Hz and 4 ms
duration yielded 109% and 106% of the response to 122 mM K+-Krebs in fetal and adult
arteries, respectively. Because these stimulation parameters yielded maximal contractile
responses, they were used in all subsequent experiments.

Measurement of MLCK Activity in Intact Ovine Carotids
As shown in Figure 6 (upper panel), both fetal and adult arteries reached peak
MLC20 phosphorylation in ~2 seconds. The slopes of these curves, which were taken as a
measure of total MLCK activity, averaged 7.39 ± 0.53 and 6.56 ± 0.29 %MLC2o
phosphorylation/sec in fetal and adult arteries, respectively. To correct for age-related
differences in MLC20 abundances, the %MLC2o phosphorylation values were multiplied
by MLC20 abundance to calculate maximal tissue rates of MLC20 phosphorylation, which
averaged 93.2 ± 4.1 and 89.4 ± 6.4 ng MLC20 phosphorylated per second per mg wet
weight in adult and fetal arteries, respectively; these values were not significantly
different. To correct for age-related differences in MLCK abundances, these activity
values were normalized relative to MLCK abundance yielding average activity values of
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0.26 ± 0.01 and 1.52 ± 0.11 ng MLC20 phosphorylated/sec/ng MLCK in adult and fetal
arteries, respectively (Figure 6 lower panel); these values were significantly different.

Discussion
Among the many significant contributions made by the late Andrew Somlyo,
perhaps one of the most important was his identification of the critical importance of
myofilament calcium sensitivity as a determinant of smooth muscle contractility (27).
This discovery fueled a rapid sequence of investigations into the mechanisms translating
changes in cytosolic calcium concentration into increased MLC20 phosphorylation and
subsequent force development (48). In light of abundant evidence that myosin
phosphatase was subject to multiple pathways of regulation (16), numerous studies have
identified arachidonic acid (13), protein kinase C (34), rho kinase (25), CPI-17 (30),
protein kinase G (50), and zip kinase (33) as regulators of myosin phosphatase activity,
and thus of myofilament calcium sensitivity. In contrast, very little attention has been
paid to the role of MLCK as a detenninant of myofilament calcium sensitivity, due in
large part to evidence suggesting that endogenous MLCK activity is subject
predominantly to inhibition and not activation (49), which diminishes its potential to
explain physiological enhancement of myofilament calcium sensitivity. Aside from this
perspective, however, multiple lines of evidence have demonstrated that myofilament
calcium sensitivity is upregulated in immature compared to mature arteries (2), as is the
relation between cytosolic calcium concentration and MLC20 phosphorylation (46).
Because this upregulation persists even in the presence of inhibition of myosin
phosphatase activity (Figure 3), developmental differences in myofilament calcium
sensitivity appear to involve significant differences in MLCK activity.
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For MLCK, multiple studies have demonstrated that changes in its activity involve
significant changes in its abundance in multiple tissue types including airway smooth
muscle (22), venous smooth muscle (31), and arterial smooth muscle (15). Consistent
with this view, Western blots revealed a 6.0-fold greater abundance of MLCK in adult
compared to fetal arteries (Figure 1). This result agreed with previous studies of the
effects of postnatal maturation on MLCK abundance in rat pulmonary arteries (6).
Regarding the MLCK isoform detected, other studies have shown that MLCK is a
product of a single gene, but has two splice variants ranging from 130-150 kDa (short
MLCK) and 208-214 kDa (long MLCK) (48). During chicken embroyogenesis, and
presumably vertebrate embryogenesis as well, the expression of mRNA and protein of
the long isofonn MLCK was more prominent (11). In our Western blots, we did not find
multiple isoforms of MLCK, or the c-terminal truncation product telokin (41), in either
age group. These studies strongly suggest that MLCK abundance increases dramatically
during postnatal maturation and this alone cannot explain the greater thick filament
reactivity observed in fetal compared to adult arteries (46).
The tissue activity for any enzyme is a product of both its abundance and its specific
activity. To examine the potential involvement of postnatal changes in the specific
activity of MLCK, the present approach focused on activity measurements made in whole
arteries instead of in broken cell preparations. Although this approach differed from the
majority of previous studies of MLCK activity, it offered multiple advantages, including
preservation of the spatial organization and interaction of MLCK with other smooth
muscle contractile proteins. Previous studies have demonstrated convincingly not only
that MLCK binds both actin and myosin with high affinity (12), but also that protein-
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protein interactions could potentially influence MLCK function (26). Another advantage
of whole artery measurements was that the endogenous concentrations of MLCK along
with its substrate and cofactors, as well as possible endogenous activators and inhibitors
were fully preserved. Previous studies have suggested strongly that the levels of many of
these proteins are labile and can change in response to numerous physiological
perturbations including development, pregnancy and hormonal treatment (8, 35, 53). In
light of the greater physiological relevance of in situ studies, a few previous studies of
MLCK function have also employed in situ measurements of MLCK activity (9, 21).
In intact arteries, the force and velocity of contraction are highly dependent on the
extent of stretch (44). Because maximal force generation in intact arteries occurs only at
optimal stretch, it follows that maximal MLCK activity should also be observable only at
optimal stretch (14). Given this consideration, the first priority of these studies was to
determine optimum length for both fetal and adult carotids using a classical functional
“length-tension” approach. Consistent with previous findings (42), adult arteries required
a significantly greater extent of stretch to attain optimum length than did fetal arteries
(Figure 2). This large magnitude of age-related difference in optimum length suggests
that measurements of in situ MLCK activity not made at optimal length could lead to
significant errors. Because previous studies of in situ MLCK activity have not always
acknowledged the importance of optimal length as a prerequisite for reliable estimation
of maximal in situ MLCK activity, some inconsistencies among such studies may arise
directly from this issue (8, 21).
Given that the extent of MLC20 phosphorylation reflects the integrated difference
between the activities of MLCK and myosin phosphatase, any estimate of MLCK activity
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in situ requires complete inhibition of myosin phosphatase. As shown by Ishihara and
colleagues (18) smooth muscle phosphatase can be potently inhibited by calyculin-A in
the sub-micromolar concentration range. Addition of an optimal concentration of
calyculin-A (30 nM) to whole arteries significantly increased the rate of MLC20
phosphorylation indicating that calyculin-A was effective in our preparations (Figure 3
upper panel). However, further validation experiments indicated that 10 pl/ml of the
Phosphatase Inhibitor Cocktail (PIC, Sigma, P2850), which contains multiple
phosphatase inhibitors (cantharidin, bromo-tetramisole and microcystin LR), was even
more effective than calyculin alone and produced an optimally effective inhibition of
phosphatase activity as indicated by greater overall values of %MLC2o phosphorylation
(Figure 3 lower panel). In light of these results, all measurements of in situ MLCK
activity included 10 pl/ml of the Phosphatase Inhibitor Cocktail. Here again, not all
previous studies of in situ MLCK activity have included optimal concentrations of
phosphatase inhibitors; the variable extent of phosphatase inhibition probably contributes
significantly to the heterogeneity among the results of such studies (8, 9, 21).
Aside from abundant evidence suggesting that MLC20 is the only known substrate
for MLCK (24), a variety of other kinases also appear capable of phosphorylating
MLC20. These include Protein Kinase A (51), Protein Kinase C (17), Rho-Kinase (4),
Integrin-Linked Kinase (52), and P21 -Activated Kinase (7). A key feature of these other
kinases, however, is that their rates of phosphorylation of MLC20 are generally much
slower than that of MLCK (36, 37), which suggests that measurements of MLC20
phosphorylation over short time courses should reflect MLCK activity almost
exclusively. To verify this concept, some measurements of MLCK activity included
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varying concentrations of ML-7 (Figure 4, upper panel), a specific inhibitor of MLCK
(45). These measurements indicated that 100 pM ML-7 maximally inhibited potassiuminduced MLC20 phosphorylation in both fetal and adult arteries. More importantly, 100
pM ML-7 completely inhibited all phosphorylation of MLC20 during a 9-second exposure
to potassium (Figure 4, lower panel), indicating that at least in fetal and adult ovine
carotid arteries, MLCK is the only kinase phosphorylating MLC20 in less than 10
seconds.
Another important concern related to in situ measurements of MLCK activity is the
rate of activation in an artery with multiple layers of smooth muscle. Upon exposure to a
chemical stimulus such as potassium, the outermost cells will be activated first and the
innermost cells will be activated only after a delay due to the time required for the agonist
to diffuse through the artery wall (23). This problem can be particularly important when
arteries of significantly different wall thicknesses are compared, as is the case for fetal
and adult ovine carotid arteries (42). To verify the importance of this problem, we
fabricated a vessel cuvette designed to enable highly accurate rapid freezing of artery
segments based on a modification of the design first published by Maass-Moreno (32).
This device made possible the activation of arterial rings with either pharmacological
agonists or electrical field stimulation delivered by large surface area platinum plate
electrodes. The key advantage of activation with electrical field stimulation was that it
produced simultaneous activation of all smooth muscle cells within the mounted segment
(23, 32). With this device, activation of smooth muscle with either 25 pM serotonin or
122 mM potassium-Krebs produced a significant increase in MLC20 phosphorylation that
reached peak magnitude in approximately 8 seconds. In contrast, activation with
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electrical field stimulation produced a much more rapid increase in MLC20
phosphorylation that reached peak magnitude in approximately 2 seconds, after which
phosphorylation levels decayed rapidly back to baseline values (Figure 5, upper panel).
Based on these results, all further measurements of MLCK activity relied on activation
only with electrical field stimulation. Further validation experiments indicated that
maximal activation of both fetal and adult arteries were attained by stimulation current at
or above 90 mA (Figure 5, lower panel).
Using our rapid-freeze apparatus, maximal activation with electrical field stimulation
during optimal inhibition of myosin phosphatase activity produced increases in MLC20
phosphorylation that were faster (as %MLC2o phosphorylated/sec) in fetal (7.4%) than in
adult (6.6%) artery segments (Figure 6, upper panel). In light of age-related differences
in MLC20 abundance, we also calculated the absolute tissue velocities of MLC20
phosphorylation and these values (as ng MLC20 phosphorylated/sec/mg wet weight) did
not vary significantly among fetal (89.4 ± 6.4) and adult (93.2 ± 4.1) arteries. This
finding agreed well with our previous findings in these artery types that maximum active
stresses (in mN/mm2) also do not vary significantly among fetal and adult arteries (42).
Together, these results suggest that both fetal and adult arteries are adapted to produce
near-equivalent rates of MLC20 phosphorylation and contractile forces, although through
much different mechanisms. When in situ MLCK activity was estimated by normalizing
the absolute tissue velocities of MLC20 phosphorylation by MLCK abundance, the fetal
values (in ng MLC20 phosphorylated /ng MLCK /sec) were almost 6-fold greater (1.52 ±
0.11) than observed in adult (0.26 ± 0.01) arteries (Figure 6, lower panel). These large
differences in MLCK specific activity appear to be counterbalanced by opposite
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differences in MLCK abundance such that overall tissue velocities in MLC20
phosphorylation, and generation of contractile force, are similar in the two age groups.
As a whole, the present results emphasize the physiological importance of changes in
MLCK activity during postnatal maturation of contractile function of ovine carotid
arteries. The data suggest that increasing postnatal expression of MLCK is closely
coordinated with parallel decreases in MLCK specific activity through unknown
mechanisms. Age-related shifts in MLCK isoform do not appear to be involved based on
Western blot results, but this conclusion requires further detailed exploration at both the
proteomic and genomic levels. Post-translational modifications of MLCK activity are
also possible, particularly in light of evidence that MLCK can serve as a substrate for
multiple kinases abundant in smooth muscle (49). Another possibility is that MLCK may
be differentially regulated by endogenous inhibitors, such as polyamines (43). Perhaps
more likely, endogenous levels of calmodulin may vary with age (10), particularly in
light of recent observations that calmodulin concentrations may be rate-limiting in some
tissues (19). In addition, age-related differences in the extent of MLCK activation may
also play a critical role, as suggested by a broad variety of evidence indicating that
calcium handling and mobilization are very different in mature and immature arteries
(39). Finally, it remains possible that the spatial organization of MLCK and MLC20 is
very different in fetal and adult arteries; activation of MLCK that is not co-localized near
MLC20 will produce neither phosphorylation nor contractile force. This possibility might
also be a consequence of the growing list of non-kinase functions attributed to MLCK
(26, 29). Aside from the mechanisms involved, the present data clearly indicate that
postnatal changes in MLCK function make an important contribution to corresponding
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changes in thick filament reactivity, myofilament calcium sensitivity, and overall
vascular contractility.
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Figure Legends
Figure 1: Abundance o fMLCK in Ovine Carotid Arteries:
Supemates from artery homogenates containing 20 [ig of total protein were loaded
on 8% SDS-PAGE gels along with varying masses of a reference standard for MLCK in
adjacent lanes. The integrated density values ofMLCK were converted to their respective
masses using a standard curve and then normalized to tissue wet weight. The results
expressed here indicate abundance relative to the fetal values. Error bars indicate SEM
for 7 fetal and 7 adult animals
Figure 2: Length-Tension Relations in Ovine Carotid Arteries:.
Carotid artery segments of fetal and adult sheep were wire mounted and stretched to
D/Do ratios ranging from 1.0 to 3.0. At each stretch ratio, contractile responses to 122
mM K+ were recorded and then normalized relative to maximum response. The vertical
error bars indicate standard errors for a total of 79 artery segments from 5 fetuses and 96
artery segments from 6 adult sheep.
Figure 3: Optimum Concentrations of Calvculin-A and Phosphatase Inhibitor Cocktail
for MLCP Inhibition.
Calyculin-A (upper panel) and Phosphatase Inhibitor Cocktail (PIC, lower panel)
were added to inhibit MLCP activity. Artery segments from both age groups were
incubated in 0, 10, 30, or 100 (nM) calyculin-A for an hour and then depolarized with
122 mM K+ for 9 seconds, then immediately frozen and analyzed for MLC20
phosphorylation using urea glycerol gels (upper panel). Total of 20 artery segments from
each group were used from 5 fetuses and 5 adult sheep. Similar measurements were
conducted with PIC at 0, 3, 10, or 30 pl/ml concentrations in 20 artery segments each
from 5 fetus and 5 adults, respectively (lower panel). The results shown indicate averages
± SEM for the number of fetal and adult sheep indicated in parentheses.
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Figure 4: Concentration and Time Dependent Effects of ML-7 on MLCK Activity.
Concentration dependent effects of ML-7 on MLCK activity were by treatment with
0, 10, 30, 100 or 300 \xM of ML-7 for 30 minutes followed by incubation with 10 pl/ml
of PIC for an hour. The segments were then instantly frozen after 9 seconds of
contraction with 122 mM K+ and analyzed for MLC20 phosphorylation (upper panel).
Time courses of MLC20 phosphorylation were then determined in the presence and
absence of 100 pM ML-7 (lower panel) by freezing at 0, 3, 6 and 9 seconds after
contraction with 122 mM K+. A total of 65 segments each from 5 fetuses and 5 adult
arteries were used for this study. All the results indicate averages ± SEM for the number
of fetal and adult sheep indicated in parentheses.
Figure 5: Validation of Activation Via Electrical Field Stimulation:
A total of 21 artery segments from three adults were wire mounted in a custom-made
rapid freeze apparatus and stimulated with either electrical field stimulation, 122 mM K+
or 25 pM 5HT and frozen at different time points (upper panel). The segments were then
extracted and analyzed for MLC20 phosphorylation using urea glycerol gels. Peak MLC20
phosphorylation was observed much earlier with electrical stimulation than with either
form of chemical stimulation.
To determine the optimal current used for electrical field stimulation, two fetal artery
segments and two adult artery segments were mounted in vitro, equilibrated at optimal
length, and electrically stimulated at 60 Hz with duration of 4 msec at 40, 50, 55, 60, 70,
75, 80, 90, and 100 mA (lower panel). The corresponding contractile responses were
normalized relative to the responses to 122 mM K+. The data shown represent the means
of 3 fetal and 3 adult artery segments. To confirm that 90 mA produced maximal
activation in all segments, each segment used was first contracted with 122 mM K+, and
the resulting contractile response was used to nonnalize all subsequent responses to EPS.
For all segments used, EPS produced more than 100% of the contractile force produced
by 122 mM K+.
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Figure 6: MLCK Velocity in Intact Ovine Carotid Arteries:
Fetal and adult artery segments were wire-mounted and positioned in the rapid freeze
apparatus, activated via electrical field stimulation, and frozen at exactly 0, 1, 2 & 3
seconds. The segments were then analyzed for MLC20 phosphorylation. The initial rate of
change of MLC20 phosphorylation was taken as a measure of MLCK velocity (upper
panel). To correct for age-related differences in MLC20 and MLCK abundances, the
%MLC2o phosphorylation ratios were multipled by the corresponding mass ratios of
MLC20/MLCK abundance (lower panel). The initial slopes (“V=”) are given for each age
group. A total of 20 artery segments from 5 fetuses and 20 artery segments from 5 adults
were used for this study. The values shown indicate averages ± SEM, and asterisks
indicate statistically significant differences between corresponding fetal and adult values.
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Abstract
We have recently shown that MLCK velocity measured in-situ is upregulated in fetal
compared to adult arteries and contributes to age related differences in contractility. The
present study tests the hypothesis that maturational down-regulation of MLCK velocity
in-situ is attributable to corresponding decreases in catalytic activity and fractional
activation of MLCK. To test this hypothesis, Vmax and Km of MLCK were estimated
under verified optimal conditions in tissue homogenates prepared from carotid arteries
harvested from term fetal lambs and non-pregnant adult sheep. Purified chicken gizzard
MLC20 served as the substrate for MLCK, and all velocity measurements included
normalization relative to absolute MLCK concentration. Fetal values of maximal MLCK
velocity (ng MLC20 phosphorylated/sec) averaged (163 ± 11), and were significantly
greater than corresponding adult values (130 ± 9). Substrate affinity values (in pM) did
not differ significantly and averaged 4.80 ± 1.20 and 3.30 ± 0.98 in fetal and adult
homogenates, respectively. When estimates of maximal MLCK activity measured in-situ
were divided by homogenate estimates of Vmax, the resulting values of fractional
activation were significantly greater in fetal, (7.20 ± 0.52%) than in adult (1.46 ± 0.07%),
homogenates. Together, these results support the hypothesis that increased enzyme
specific activity and increased fractional activation both contribute to the greater MLCK
velocities observed in fetal compared to adult ovine carotid arteries.

Key words
Enzyme kinetics, myofilament calcium sensitivity, postnatal maturation, thick
filament reactivity.
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Introduction
The transition from fetal to postnatal life involves numerous dramatic changes in
vascular structure and reactivity. These changes clearly involve altered patterns of
sarcolemmal receptor expression and calcium handling that continuously alter
pharmacomechanical coupling throughout fetal and postnatal maturation (24, 35). An
important component of these maturational adjustments are a gradual postnatal decrease
in the magnitude of agonist-induced myofilament calcium sensitization (2, 3, 5). These
decreases in myofilament calcium sensitization involve altered relations between
cytosolic calcium concentration and the extent of myosin light chain phosphorylation,
which is defined as thick filament reactivity (25, 32). In turn, this altered thick filament
reactivity is attributable in large part to enhanced rates of myosin phosphorylation, in
situ, despite a lower abundance of myosin light chain kinase in fetal relative to adult
arteries (32).
Whereas multiple previous studies have documented that MLCK abundance and
activity are often tightly correlated (16, 17, 21, 31), studies of fetal and postnatal
development have demonstrated the opposite correlation; in immature arteries the MLCK
abundance is low but activity is high (8, 9). Our previous studies agree with this latter
finding. It remains possible however, that age-related differences in substrate
concentration could be involved. Similarly, the expression of essential cofactors such as
calmodulin could be reduced in mature arteries, although published evidence argues
against this possibility (10). In adult arteries, elevated abundances of endogenous
inhibitors of MLCK activity, such as polyamines (30) or telokin (14), might also explain
reduced rates of myosin phosphorylation. In addition, age-dependent post-translational
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modification of MLCK resulting in altered specific activity also remains possible; studies
with Protein Kinase A, Protein Kinase C, and Calcium-Calmodulin Kinase II have
demonstrated that each of these kinases can attenuate MLCK specific activity (34). Agerelated differences in the extent of activation of MLCK could also play a significant role,
particularly in light of abundant evidence demonstrating that agonist-induced increases in
cytosolic calcium vary considerably with fetal and postnatal age.
The present studies examine the MLCK-dependent mechanisms potentially
responsible for greater rates of MLC20 phosphorylation observed in immature compared
to mature arteries. In particular, these studies focus on the two mechanisms most likely to
play a role in age-related differences in MLC20 phosphorylation, namely MLCK specific
activity and fractional activation. To explore the importance of these mechanisms, a
dilute homogenate assay was developed to directly estimate the kinetics of MLCKmediated MLC20 phosphorylation in homogenates prepared from fetal and adult ovine
carotid arteries. The estimates so obtained enabled direct calculation of the maximal
extent of fractional activation observed in situ.

Materials and Methods

General Preparation
Carotid arteries were obtained from non-pregnant adult female sheep (18-24 months
old) and near term (~140 days gestation) fetuses. To obtain fetal arteries, pregnant ewes
were anesthetized with 30 mg/kg pentobarbital, intubated and then placed on 1.5- 2.0 %
halothane. Each fetus was then exteriorized through a midline vertical laparotomy and
killed by rapid removal of the heart. Adult animals were sacrificed by intravenous
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administration of 100 mg/kg pentobarbital. Carotid arteries were dissected and cleaned of
extraneous connective and adipose tissue. The endothelium was removed by passing a
roughened needle through the lumen, after which arteries were immediately frozen in
liquid nitrogen and stored at -80 °C until homogenized. All procedures used in these
studies were approved by the Animal Research Committee of Loma Linda University and
adhered to all policies and practices outlined in the National Institutes of Health Guide
for the Care and Use ofLaboratory Animals

Preparation of Carotid Artery Homogenates
Frozen carotid arteries (~150 mg per animal) were homogenized in ice cold buffer
containing 20 mM imidazole, 1 mM cysteine, 60 mM KC1, 1 mM MgCL, 10 mM sodium
azide, 0.25 mM PMSF, and 1 mM DTT, at pH 7.5. The homogenization buffer also
contained phosphatase inhibitor cocktail (Sigma P-2850) at a concentration of 10 pL/mL
buffer and 0.5% protease inhibitor cocktail (Sigma, P8340). Homogenization was carried
out for 15 minutes at 4 °C using a motor-driven glass-on-glass mortar and pestle and then
centrifuged for 1 minute at 6000 G after which an aliquot of supernatant was taken for
protein determination. Final adjustments in protein concentration were made to assure
that the amount of MLCK in each homogenate was similar. Fresh homogenates were
prepared daily for each enzyme velocity measurement.

Determination of MLCK Abundance in Artery Homogenates
From each artery homogenates, 15 pg of total protein were loaded on a 15-lane, 8%
SDS-PAGE gel, and run at 15 mA for 90 minutes and then transferred onto nitrocellulose
membrane. The membrane was blocked overnight at 4° C with 5% non-fat dry milk in 20
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mM Tris HC1 at pH 7.5, 500 mM NaCl and 0.1% Tween-20 and then probed with mouse
anti-MLCK primary antibody (Sigma, M7905) at 1:7,000 dilution for 2 hours. Primary
antibody-antigen complexes were detected with a goat anti-mouse secondary antibody
(Pierce, #1858413), and visualized using direct photon capture with a CCD camera
(Alphalnnotech, Chemi-Imager). Purified chicken gizzard MLCK was used as reference
standard to quantify absolute amount of MLCK present in homogenates.

Determination of Optimum Calcium and Calmodulin Concentrations
for Activating MLCK

Fetal and adult homogenates were adjusted to contain equivalent amounts of MLCK
both before and after a 400-fold dilution. Exogenous MLC20 was added to the dilute
homogenates to raise MLC20 concentration to 1.5 pM. Aliquots of both homogenate
concentrations were incubated with 0, 0.3, 0.6, or 1 pM calmodulin for 20 minutes at 4
°C and then for 10 minutes at 37 °C. Next, calcium at 0, 0.3, 1, 3 or 10 mM was added
with 1 mM ATP to initiate the reaction. The reaction was terminated at exactly 0, 1, 2 and
3 seconds by adding ice cold 10 mM EDTA and then transferring the samples to dry ice.
The samples were then analyzed for MLC20 phosphorylation using 10% urea glycerol
gels. These gels were run for 150 minutes at a constant voltage of 200V and then
transferred onto nitrocellulose membrane at a constant current of 50 mA for 180 minutes.
Membranes were blocked with 5% milk in TBS (20 mM Tris HC1, 500 mM NaCl, pH
7.5) for 90 minutes. After blocking, the membranes were incubated in primary antiMLC20 antibody (MY-21, Sigma M4401) at 1:300 dilution with 5% milk in Tween-TBS
for 3 hours, followed by incubation in goat anti-mouse secondary antibody (Pierce,
#1858413 at 1:1000 dilution) conjugated with horse radish peroxidase for 90 minutes. All
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washes were carried out with Tween-TBS containing 5% milk. Antibody-antigen
complexes were detected by chemiluminescence using a mixture of equal volumes of
enhanced luminol reagent and oxidizing reagent. Membranes were then scanned to
determine the integrated optical density values of both phosphorylated and
unphosphorylated MLC20 bands using a Chemi Imager, (Alphalnnotech). Masses (ng) of
MLC20 phosphorylated were determined using a standard curve prepared from multiple
masses of purified MLC20 run on each gels. The slope of the relation between ng MLC20
phosphorylated and time was taken as a measure of MLCK activity.

Determination of Optimum Concentration of Phosphatase Inhibitor Cocktail (PIC)
Tissue homogenates containing equivalent amounts of MLCK were collected and
incubated with 0, 3, 10, & 30 (pL/mL) of PIC for 20 minutes at 4 °C in a final volume of
40 pL. Next, the homogenates were brought up to 37 °C and maintained at that
temperature for 10 minutes after which 3 mM calcium and 1 mM ATP were added to
activate MLCK. After exactly 3 seconds, the reaction was rapidly terminated by adding
ice cold 10 mM EDTA and the homogenates were transferred to dry ice. The samples
were then analyzed for MLC20 phosphorylation using 10% urea glycerol gels as described
in preceding section “Determination of optimum calcium and calmodulin concentrations
for activating MLCK.”

Effects of Protein Kinase Inhibitors on MLCK Velocity
Suggestions from multiple previous studies that PKA (1), PKC (26), and CaMKinase II (13) can inhibit MLCK activity necessitated a series of experiments to verify
that the observed age-related variations in MLCK activity were not due to differential
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inhibition by these kinases. Artery homogenates were incubated with H-89 (PKA
inhibitor) at 0, 0.05, 0.15 or 0.5 juM-for 20 minutes at 4 °C and then for 10 minutes at 37
°C. MLCK velocity was measured in presence of this inhibitor by adding 3 mM calcium
and 1 mM ATP to initiate the reaction. The reaction was terminated at exactly 0, 1, 2 & 3
seconds by adding ice cold 10 mM EDTA and then transferring the samples to dry ice.
The MLCK velocity was calculated as the rate of change of MLC20 phosphorylation as
determined from band densities measured in 10% urea glycerol gels. Similar
measurements were made in the presence of calphostin-C (PKC Inhibitor) at 0, 0.05,
0.15, 0.5 pM or with KN-93 (CaM Kinase-II inhibitor) at 0, 1, 3, or 10 pM
concentrations, respectively.

Determination of V max &Km of MLCK
To retard the reaction rate enough to enable accurate measurements of product
(phosphorylated MLC20) accumulation, and also negate the influence of endogenous
substrate concentration, the artery homogenates were diluted approximately 400-fold.
MLCK concentrations were standardized across all homogenates using Western blots
with purified chicken gizzard MLCK as absolute standards on each gel. The maximal
velocity of MLCK was determined by incubating artery homogenates with purified
chicken gizzard myosin light chain at 1.5, 3, 5, 7.5, 10, 15 & 20 pM for 10 minutes at 37
°C. MLCK activity was then initiated, terminated and quantitated as described in the
section “Determination of optimum calcium and calmodulin concentrations for activating
MLCK.”
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Calculations and Statistics
All curve fitting was performed using least-square error minimization routines. Non
linear fits for concentration-response relations were fit as rectangular hyperbolae. Non
linear fits for standard curves (optical density vs. mass) were fit to the logistic equation.
Coefficients of fit for the standard curves were used to prepare inverse forms of the
logistic equation that enabled direct calculation of sample masses from band optical
densities. Linear fits for the Lineweaver-Burke (double-reciprocal) plots were performed
via linear regression. The MLC20 masses were calculated directly from optical density
values using standard curves prepared from known absolute masses of purified MLC20
loaded on each gel. Apparent specific activity in homogenates was calculated by dividing
estimates of homogenate Vmax by the corresponding mass of MLCK measured in the
same homogenate. Throughout the text, all values indicate the mean ± the standard error
for the number of animals indicated; values of N refer to the numbers of animals and not
the numbers of segments or experiments. Unpaired comparisons between two variables
were performed using a Behren’s-Fisher comparison with pooled variance. All data sets
were verified to be normally distributed using SPSS vl6. Unless stated otherwise, a
statistical power of 0.8 was attained for all comparisons yielding no significant
difference. In all cases, statistical significance implies P<0.05.

Results
A total of 3.4 gm and 2.3 gm of carotid arterial tissue were used for these studies.
These tissues were harvested from a total of 16 fetuses and 16 adult sheep respectively.
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MLCK Abundance in Artery Homogenates
Fetal artery homogenates contained 2.43 ± 0.21 ng MLCK/|ug protein and adult
homogenates contained 8.82 ± 0.80 ng MLCK/pg protein. For undiluted samples, 145 ng
of MLCK from both fetal and adult homogenates were taken for measuring MLCK
velocity.

Optimum Concentrations of Calcium and Calmodulin for MLCK
In undiluted artery homogenates the MLCK velocity (ng MLC20 phosphorylated/sec)
observed in the presence of 0.3 pM calmodulin and 3 mM calcium averaged 41.9 ± 2.0 in
fetal arteries and 32.2 ± 10.0 in adult arteries. Changes in either of these calmodulin or
calcium concentrations did not significantly increase MLCK velocity in either undiluted
or diluted fetal or adult artery homogenates (Figure 1). Indeed, the results revealed that
concentrations of calmodulin greater than 0.3 pM tended to decrease MLCK velocity in
both fetal and adult homogenates. Given these results, all measurements of maximal
MLCK velocity were performed at 0.3 pM added calmodulin and 3 mM added calcium.

Optimum Concentration of Phosphatase Inhibitor Cocktail
Sigma’s Phosphatase Inhibitor Cocktail (PIC) inhibited MLCP in a concentrationdependent manner in both fetal and adult arteries (Figure 2). The mass of MLC20
phosphorylated in 3 seconds averaged 60.0 ± 3.3 ng in fetal arteries and 52.9 ± 3.9 ng in
adult arteries, in the presence of 10 pL/mL of PIC. Increases in PIC concentration above
10 pL/mL did not further increase the mass of MLC20 phosphorylated. Based on this
result, all subsequent measurements of MLCK velocity included PIC at a concentration
of 10 pL/mL.
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Effect of Protein Kinase Inhibitors on MLCK Velocity
In fetal tissue homogenates, MLCK velocities (ng MLC20 phosphorylated/sec) were
not significantly different in control samples (42.2 ± 13.1) and in samples treated with 0.5
pM H-89 (22.5 ±9.1). However, in adult artery homogenates MLCK velocities were
significantly greater in control samples (38.0 ± 7.4) than in samples treated with 0.5 pM
H-89 (18.2 ± 3.6). Similar studies of MLCK velocities in the presence of 0.5 pM
calphostin-C showed no significant differences compared to control values in either fetal
(24.2 ± 5.8) or adult (27.9 ± 3.7) artery homogenates. In addition, MLCK velocities in the
presence of 3 pM KN-93 were significantly lower than control values in both fetal (15.0
±6.7) and adult (13.9 ± 3.6) homogenates. As these results did not exhibit any increase in
MLCK velocities (Figure 3), kinase inhibitors were not added to homogenates used to
determine maximal MLCK activities.

Age Related Differences in VmaX and Km Values for MLCK
MLCK velocities (ng MLC20 phosphorylated /sec) exhibited classical hyperbolic
substrate dependence in both fetal and adult homogenates (Figure 4). As determined by
non-linear regression, estimates of Vmax for MLCK in fetal homogenates (163 ± 11) were
significantly greater than in adult homogenates (130 ± 9). The Km values were not
significantly different in fetal samples (4.8 ± 1.2 pM) and adult (3.3 ± 1.0 pM) samples.
The kinetic values obtained by non-linear regression were not significantly different than
those obtained by Lineweaver-Burke analysis for either fetal or adult homogenates.

61

Age Related Differences in Homogenate Specific Activity and Fractional
Activation of MLCK
To estimate the specific activities of MLCK, values of ng MLC20 phosphorylated/sec
were divided by the absolute MLCK mass in each assay to obtain velocity values in units
of ng MLC20 phosphorylated/sec/ng MLCK. The resulting values (Figure 5) were
significantly greater in fetal samples (20.6 ± 1.3) than adult samples (18.0 ± 1.28). To
calculate in situ fractional activation of the enzyme, the MLCK specific activity (in units
of ng MLC20 phosphorylated/sec/ng MLCK) measured in our previous studies in situ
were divided by apparent specific activity obtained in the homogenates. These ratios
indicate that maximal in situ fractional activation in fetal arteries (7.20 ± 0.52%) is
significantly greater than adult arteries (1.46 ± 0.07%).

Discussion
MLCK is a dedicated serine/threonine kinase that phosphorylates only T18 and S19
of MLC20 to initiate smooth muscle contraction (18). When activated by calciumcalmodulin (33), it is a very fast enzyme that can phosphorylate MLC20 in as little as 2
seconds following nerve stimulation in some preparations (6, 22). To a certain extent,
MLCK competes with other kinases, including protein kinase A (36), rho-kinase (7), and
integrin-linked kinase (11), for the phosphorylation sites on MLC20- In contrast to
MLCK, the rates of phosphorylation of MLC20 by these other kinases is relatively slow
(23), which provides a convenient basis for the separation of their effects from those of
MLCK. Correspondingly, when MLC20 phosphorylation was measured over a short
duration in the absence of added calcium and calmodulin, MLC20 phosphorylation did not
change significantly from basal levels suggesting that MLCK was the only kinase
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responsible for the MLC20 phosphorylation observed in the artery homogenates (Figure
1). Correspondingly, MLCK activation yielded maximal rates of MLC20 phosphorylation
in the presence of 3 mM calcium and 0.3 pM calmodulin. Calmodulin at concentrations
above 0.3 pM produced no further increases in MLCK velocity. In light of these results,
which agreed well with other MLCK homogenate studies (21), all measurements of
MLCK velocity included 3 mM calcium and 0.3 pM calmodulin.
Given that the extent of MLC20 phosphorylation reflects the integrated difference
between the activities of MLCK and myosin phosphatase, any estimate of homogenate
MLCK activity requires complete inhibition of myosin phosphatase. In arterial smooth
muscle, the predominant phosphatase that dephosphorylates MLC20 is in the PPlc family
(12), which is potently inhibited by cantharidin and microcystin (20). MLC20 is also
potentially subject to non-specific dephosphorylation by alkaline phosphatase,
particularly in homogenates (29). To defeat these phosphatase activities, the artery
homogenates included a commercially prepared mixture (Sigma P-2850) of cantharidin,
microcystin, and bromotetramisole (an alkaline phosphatase inhibitor). As indicated in
Figure 2, maximal levels of MLC20 phosphorylation were attained in both fetal and adult
homogenates treated with 10 pl/ml of the phosphatase inhibitor cocktail. All subsequent
homogenate experiments contained this concentration of these inhibitors.
Another complication in measurements of MLCK activity is the possible presence of
endogenous inhibitors of the enzyme (14, 30). The approach taken to negate this
complication was to develop an artery homogenate preparation in which MLCK
concentration was diluted approximately 400-fold. This dilution offered multiple
advantages. First, it eliminated any possible effects of unknown endogenous inhibitors or
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activators of MLCK. Second, it essentially eliminated any possible effects of differences
in endogenous substrate concentration. Third, it retarded the rate of MLC20
phosphorylation, which enabled more accurate measurements of reaction rate. Finally, it
eliminated any possible age-related differences in calmodulin concentration (10).
In situ, MLCK activity can potentially be attenuated by phosphorylation of the
enzyme by several different kinases (34). Among these, Protein Kinase A was the first
discovered to reversibly inhibit MLCK (1). Not long after this discovery, Nishikawa et al.
reported that Protein Kinase C could also reversibly inhibit MLCK activity (26).
Subsequently, Hashimoto and Soderling (13) further reported that Calcium-Calmodulin
Kinase II could effectively inhibit MLCK activity. In light of this evidence, the
experimental design included a series of validation experiments to confirm that the
inhibitory activities of protein kinase A, protein kinase C, and calcium-calmodulin kinase
II on MLCK were negligible in the homogenates used to measure MLCK activity.
Whereas selective inhibition of an inhibitory kinase should increase overall MLCK
activity, this result was not observed following selective inhibition of PKA by H-89, PKC
by calphostin, or CaM Kinase II by KN-93 (Figure 3).
Definition of the optimal conditions for our artery homogenates enabled
measurements of MLCK activity at varying MLC20 concentrations. The use of purified
chicken gizzard MLC20 in these measurements eliminated any possible effects due to agerelated differences in MLC20 abundance or isoform (15). This approach revealed that
MLCK maximal velocity was slightly but significantly greater in fetal (163 ± 11 ng
MLC20 phosphorylated/sec) than adult (130 ± 9 ng MLC20 phosphorylated/sec)
homogenates (Figure 4). In contrast, estimates of substrate affinity (Km) were not
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significantly different in fetal (4.8 |nM) and adult (3.3 jaM) homogenates. When
homogenate velocities were divided by the equivalent mass of MLCK in each assay tube
to estimate apparent MLCK specific activity, the calculated values (in ng MLC20
phosphorylated/sec/ng MLCK) were slightly but significantly greater in fetal (20.6 ± 1.4)
than in adult (18.0 ± 1.3) homogenates (Figure 5, left panel). Together, these data are
consistent with the findings of Belik obtained in rat pulmonary arteries (8), and suggest
that small but important differences exist between fetal and adult MLCK specific activity.
Even though the estimates of apparent MLCK specific activity were greater in fetal
than adult artery homogenates, the difference appears too small (-14%) to explain the
much larger difference in apparent MLCK specific activity previously observed in situ
(-6-fold). This finding strongly suggests that factors other than just MLCK abundance
and specific activity contributed to the age-related differences in MLCK velocity
observed in situ. One of the most likely factors contributing to the observed age-related
differences in MLCK activity in situ, is fractional activation. Activation of MLCK
typically follows smooth muscle cytosolic calcium concentration, and this variable is
regulated very differently in mature and immature arteries as shown in multiple previous
studies (4), (24). In support of this hypothesis, estimates of in situ fractional activation
based on the homogenate values of Vmax indicate it to be several-fold greater in fetal
(7.20%) than in adult (1.46%) arteries (Figure 5, right panel). This finding suggests that
physiological activation of MLCK varies dramatically with postnatal age.
Other factors could also potentially contribute to age-related differences in the
kinetics of MLC20 phosphorylation. One possibility is that age-related differences in
calmodulin abundance in situ might play a role, although the limited evidence available
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indicates that in situ calmodulin availability is greater in adult than in fetal tissues (10).
Another intriguing possibility is that age-dependent differences in MLC20 isoform with
different kinetic influences may play some role as suggested by Inoue (15). MLCK
activity might also be influenced by age-dependent post-translational modification
through a mechanism that is sensitive to homogenization. This effect might help explain
the small differences in MLCK kinetics observed in the homogenates. Because the only
known post-translational modification of MLCK activity is inhibitory phosphorylation
(34), this effect would require a greater extent of inhibitory phosphorylation of adult
compared to fetal MLCK, in situ. Age-related differences in telokin expression probably
were not involved because this endogenous MLCK inhibitor was not detected.
Alternatively, it remains possible that the spatial organization and colocalization of
MLC20 and MLCK could also play a major role (34), particularly if the relative
distribution of these two molecules changes during postnatal development as suggested
by studies of chicken gizzard (27). This possibility is particularly attractive given the
growing list of non-contractile functions assigned to MLCK (19).
Aside from the mechanisms potentially responsible for age-related differences in the
kinetics of MLC20 phosphorylation, it is important to note that the active stresses
produced by fetal and adult arteries under identical conditions of activation are not
significantly different (28). From this perspective, it is clear that the physiological
function of MLCK is highly specialized in both fetal and adult arteries. A key feature of
this specialization is that both the apparent specific activity and maximal fractional
activation of MLCK are significantly greater in fetal than adult arteries. Together, these
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adaptations appear to counterbalance the markedly reduced expression of MLCK that is
characteristic of fetal arteries.
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Figure Legends
Figure 1: Optimum Calcium and Calmodulin Concentrations Required to Activate
MLCK.
Undiluted artery homogenates containing equivalent amounts of MLCK were
incubated for 30 minutes with 0, 0.3, 0.6 or 1 qM calmodulin, then activated with 0, 0.3,
1, 3 or 10 mM calcium and 1 mM ATP, and frozen at 0, 1, 2 & 3 seconds. MLCK
velocity was estimated as the rate of MLC20 phosphorylation based on measurements
made with urea glycerol gels. The upper panel and lower panels indicate average
velocities ± SEM for 3 adult and 3 fetal sheep, respectively. Similar results were also
obtained in diluted artery homogenates.
Figure 2: Optimum Concentration of Phosphatase Inhibitor Cocktail for ML CP
Inhibition
Concentration dependent inhibition of MLCP by Phosphatase Inhibitor Cocktail
(PIC) was evident in both fetal and adult arteries. The artery homogenates were incubated
in 0, 3, 10, or 30 pl/ml PIC for 30 minutes, activated with 3 mM calcium and 1 mM ATP,
and then rapidly frozen at exactly 3 seconds. MLC20 phosphorylation was measured using
urea glycerol gels. The results indicate averages ± SEM for 3 animals in each group.
Figure-3: Effects of Protein Kinase Inhibitors on MLCK Velocity
Artery homogenates containing equivalent amounts of MLCK were incubated with
one of four different concentrations of protein kinase inhibitors for 30 minutes followed
by activation with 3 mM calcium and 1 mM ATP and rapid freezing at 0, 1, 2, or 3
seconds. Top, middle and lower panels indicate MLCK velocities in the presence and
absence of H-89 (PKA inhibitor), Calphostin-C (PKC inhibitor) and KN-93 (CaM
Kinase-II inhibitor) for 4 animals for each group. Vertical error bars indicate standard
errors. None of the inhibitors significantly increased the extent of MLC20 phosphorylation
in either age group.
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Figure-4: Age Related Differences in Vmax & Km Values for MLCK
Artery homogenates containing equivalent amounts of MLCK were incubated for 10
minutes with different concentrations (1.5, 3, 5, 7.5, 10, 15, or 20 gM) of purified
chicken gizzard MLC20- MLCK velocities exhibited classical substrate dependence in
both age groups. Estimates of kinetic parameters obtained via nonlinear regression agreed
well with those obtained by Lineweaver-Burk analysis (inset). The Km values calculated
via nonlinear regression are indicated in the right panel. The results represent averages
from 6 animals in each group. Vertical error bars indicate standard errors.
Figure-5: Age Related Differences in the Apparent Specific Activity and Fractional
Activation ofMLCK
Apparent specific activity was calculated as the estimated maximum velocity divided
by MLCK content (left panel). Fractional activation of the in situ enzyme was calculated
as the ratio of maximal velocity measured in intact arteries to the maximal velocity
measured in the homogenates. Shown are averages for 6 animals from each group for
specific activity measurements and 5 animals from each group for fractional activation.
Vertical error bars indicate standard errors for the numbers of animals indicated in
parentheses.
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Abstract
Myosin light chain kinase (MLCK) is an important enzymatic regulator of vascular
contractility that phosphorylates the regulatory protein, myosin light chain 20 (MLC2o)We have recently demonstrated that the in-situ specific activity of MLCK is strikingly
greater in fetal compared to adult sheep carotid arteries. Because cell-specific splicing
isoforms of myosin-related genes have been identified in vascular smooth muscle,
defining a late stage in the differentiation pathway from the synthetic to contractile
phenotype, we tested the hypothesis that developmental alteration in MLCK activity may
be at least partially dependent on developmental regulation of MLC20 isoforms. MLC20
was sequenced using a combination of biochemical purification and electron-spray
ionization-mass spectrometry (ESI-MS). Our results demonstrate the presence of two
isoforms of MLC20 with high level of amino acid sequence conservation in both Nterminal and C-terminal regions of ovine MLC20. Isoform 1 closely resembles chicken
MLC20 and is expressed in both fetal and adult ovine arteries. Isoform 2 resembles mouse
MLC20 and is expressed in adult tissue only. These findings support our hypothesis that
differential expression of these MLC20 isoforms with developmental age may be involved
in alteration of MLCK activity.

Key Words
Postnatal maturation, regulatory myosin light chain, protein sequences.
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Introduction
We have recently shown that myosin light chain kinase abundance is higher in adult
over fetal smooth muscle cells from extracranial sheep arteries, but in-situ specific
activity is strikingly enhanced in fetal over adult smooth muscle cells. The underlying
mechanisms for this developmentally regulated difference are not clear; one possibility is
differential substrate (MLC20) reactivity owing to altered structural properties of
functional significance, or to altered substrate stability. Altered structural properties of
MLC20 may be due to altered post-translational modification of the substrate protein, or
due to the expression of substrate isoforms. The phosphorylation of MLC20 at canonical
sites is well documented, but the presence of MLC20 isoforms in diverse mammalian
tissues has not been addressed with the high resolution and sensitivity afforded by mass
spectrometry. The present study examines the age-dependent occurrence of MLC20
isoforms in vascular tissue using electrospray-injection mass spectrometry.

Materials and Methods

General Preparation
Vascular smooth muscle tissue was obtained by collecting arteries from non
pregnant adult female sheep (18-24 months old) and near term (-140 days gestation)
fetuses as previously described. Arteries were cleaned of extraneous connective tissue
and endothelium was removed by passing a roughened needle through the lumen.
Arteries were then immediately frozen in liquid nitrogen and stored at -80 °C until
homogenized. All procedures used in these studies were approved by the Animal
Research Committee of Loma Linda University and adhered to all policies and practices

81

outlined in the National Institutes of Health Guide for the Care and Use of Laboratory
Animals

Extraction of MLC20 from Arterial Tissue
About 25g of arteries were pulverized in liquid nitrogen using stainless steel mortar
and pestle as previously described. The pulverized arteries were then homogenized in 6
volumes of buffer containing 50 mM KC1, 20 mM Tris, 15 mM beta-mercaptoethanol at
pH 8 followed by centrifugation for 15 minutes at 5010G .The supernatant is discarded
and washing is repeated with the same buffer along with 1% triton-XIOO. Following this
washing, the artery homogenate is washed another 4 times with the same buffer with out
any triton-XIOO. The pellet is collected and extracted for MLC20 by continuously stirring
with buffer containing 8 M Urea, 20 mM Tris, 15 mM beta-mercaptoethanol for 2 hours
at room temperature. After extraction, large proteins were precipitated by adding buffer
containing 95% Ethanol and 15 mM beta-mercaptoethanol and stirring for 1 hour at 4 °C
followed by centrifugation at 14160G for 20 minutes. The supernatant containing MLC20
is collected.

Ion-Exchange Chromatography of MLC20
About 35g of preswelled DE52 is equilibrated overnight in buffer containing 20 mM
Tris and 15 mM beta-mercaptoethanol at 4 °C by continous stirring. The DE52 is allowed
to settle and when a distinct line appears between DE52 and the buffer, the supernatant is
siphoned off carefully. MLC20 extract is then added to this reconstituted DE52 and stirred
overnight at 4 °C. DE52 is then poured into column and proteins are eluted with 150 mM
KC1, 10 mM Tris, 15 mM beta-mercatoethanol overnight at 4 °C. The eluant is collected
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as 120 fractions each containing 4 mL volume and analyzed for MLC20 using dot-blot
method followed by immunoblotting.

Gel filtration Chromatography
The fractions containing MLC20 are identified and pooled together and then
precipitated with ammonium sulphate followed by an overnight dialysis using dialyzing
solution containing 5M urea, 10 mM EDTA at pH 10.6. The dialysate is then run on S200 gel filtration column. A total of 120 fractions were collected overnight each
containing 2 mL volume and then analyzed for MLC20 using dot-blot method followed by
immunoblotting. The purity of the fractions containing MLC20, is further verified by
running them on 15% SDS gels and staining with sypro ruby red dye.

Electrospray-Injection Mass Spectrometry (esi-ms)
For mass spectrometric analysis in-gel proteolysis by trypsin and ArgC were
performed essentially as described by Shevchenko (Nature Protocols, 2006). Protein
acylation before tryptic digest was performed to increase retrieval of hydrophilic Nterminal fragments. Proteolytic fragments were resolved and identified by electrosprayinjection mass spectrometry (ESI-MS) on a Waters/Micromass Q-TOF Ultima instrument
at the LEU mass spectrometry core.

Results
A total of 40 gm arterial tissue was used for these studies. These tissues were
harvested from a total of 40 fetuses and 20 adult sheep respectively
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Identification of Fractions Containing MLC20 from Ion-Exchange Chromatography
Extraction supernatant containing MLC20 was bound to DE52 resin and eluted with
150 mM KCL The fractions were then assayed for total protein content and MLC20. The
fractions from #22 to #35 showed high protein content as well as greater MLC20
abundance.

Purification of MLC20 by Gel Filtration
In line with the literature, only few fractions (#62 to #68) of the S-200 eluate
containing MLC20 were free of apparent contaminations by protein species of high
molecular weight (Fig. 4A). Further purification by 15% SDS-PAA of pooled S-200
eluate was performed (Fig. 4B). A single band migrating at 20kD confirmed the presence
of purified MLC20-

Identification of Two Distinct Isoforms of MLC2oby Electrospray-Injection
Mass Spectrometry (esi-ms)
Two distinct isoforms of smooth muscle ovine MLC20 were identified in band 2.
Isoform 1 closely resembles chicken MLC20 and is expressed in adult and fetal tissue.
Isoform 2 closely resembles mouse MLC20 and is expressed in adult tissue only.

Discussion
In contrast to most previous studies of smooth muscle MLC expression, two distinct
isoforms of smooth muscle ovine MLC20 with essentially the same molecular weight
were identified in adult arteries.
The first ovine isoform is virtually identical to the major isoform of chicken gizzard
MLC20, except for a possible deletion of the most N-terminal amino acids, as seen in
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bovine smooth muscle MLC20. The first ovine isoform is expressed in both adult and fetal
arteries.
The second ovine isoform is virtually identical to rat smooth muscle MLCioand
strongly resembles the porcine MLC3 isoform, except for a possible deletion of the most
N-terminal amino acids, as seen in bovine smooth muscle MLC20. The second ovine
isoform is expressed in adult tissue only, establishing the paradigm of developmentally
expressed MLC2oisoforms.
The absence of the N-terminal four coding amino acids of the MLC2oConsensus
sequence from sheep MLC20 needs to be confirmed by an alternative proteolytic digestion
procedure (V8 protease).
Most amino acid substitutions (which also define the porcine MLC3 isofonn) in
ovine vascular isoform 2 are seen within a twelve amino acid stretch between residues
112 and 124 (conventional numbering), directly C-terminally contiguous to the first
putative helix of the second EF hand. Another unique isoform substitution (DA) is
located 12 amino acids before the end of the last putative helix in the first large EF hand.
Isoform-specific amino acid substitutions are seen within the first and second EFHand regions in positions consistent with a possible role in exerting influence on the
exact positioning of adjacent helical structures
These results constitute the first demonstration of smooth muscle MLC20 isofonns in
mammalian tissues, specifically in vascular tissue. Whereas the source tissue includes
multiple cell types (endothelia, smooth muscle cells, fibroblasts), only smooth muscle
cells are known to contain substantial amounts of smooth muscle-specific MLC20.
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Amino acid substitutions of the porcine MLC3 type in ovine MLC isoform 2 may
influence the exact positioning of helical elements within the functional domains of
MLC20 and thereby affect interactions with MLCK and/or myosin cross-bridges.
Age-related variations in MLC isoform expression may help explain developmental
differences in regulation of myofilament calcium sensitivity and overall vascular
contractility.
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Figure Legends
Figure 1: Extraction and Ion-Exchange Chromatography of MLCw
MLC2o-was prepared from snap-frozen sheep arteries. Ethanolic extraction
supernatant containing MLC2o-was bound to DE52 resin and eluted at 150 mM KCL
MLC2o-Containing fractions were identified by immunoblot, pooled and further purified
by gel filtration over a S-200 column.

Figure 2: Purification of MLCyn by Gel Filtration
Crude MLC20 eluted from the DE52 column was concentrated by ammonium sulfate
precipitation, dialyzed against 5M urea, 10 mM EDTA at pH 10.6, and eluted from an S200 column. Eluate fractions containing MLC20 were identified by immunoblot.

Figure 3: Analytical and Preparative Gels o f Ovine Smooth Muscle MLCw
The eluants from S-200 column were analyzed on 15% SDS-PAA gels stained with
SYPRO Ruby, to assess apparent purity. An increasing amount of carbonic anhydrase is
also loaded on the gels to provide a reference standard to quantify the amount of MLC20
present in the samples.

Figure 4: Alignment of Isoform-Specific Amino Acid Substitutions
Proteolytic fragments were resolved and identified by electrospray-injection mass
spectrometry (ESI-MS) on a Waters/Micromass Q-TOF Ultima instrument.
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CHAPTER 5
CONCLUSIONS & FUTURE DIRECTIONS

The present studies investigated the hypothesis that age-related differences in
myofilament calcium sensitivity involve upregulation of myosin light chain kinase
activity in fetal compared to adult carotids. To test this hypothesis, as the first specific
aim, MLCK and MLC abundances in fetal and adult carotid arteries were measured. The
results clearly showed that MLCK abundance is about 6 fold greater in adult compared to
fetal carotid arteries. However, MLC abundance remained relatively same in both fetal
and adult carotid arteries. From these results it is clear that expression of myosin light
chain kinase protein is regulated very differently in fetus and adult. This could be due to
differences in either protein synthesis or protein degradation. Further studies can be
conducted using molecular biology techniques like RT-PCR to test mRNA abundance of
MLCK in both fetal and adult arteries. These studies will clarify if the differences in
MLCK protein abundance are due to differences in mechanisms involved in protein
synthesis. Using these techniques, the transcription rate and translation efficiency of
MLCK can also be determined. Together these studies will provide a basis to explain the
6 fold greater abundance of MLCK protein in adult compared to fetal arteries. As the
abundance of myosin light chain did not change significantly it is possible that the
regulatory mechanisms involved in its synthesis are highly conserved. As myosin is a
highly conserved protein expressed in most of the eukaryotic cells, it is possible that its
expression is not influenced by age dependent changes.
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In the second specific aim, MLCK in-situ specific activity is measured. For this
purpose, the conditions required for maximal activation of MLCK were optimized and
verified. These experiments also necessitated the designing of a custom-made rapid
freeze apparatus that can maximally activate MLCK by electrical field stimulation and
simultaneously freeze the tissue at very short intervals of time using a computer
controlled solenoid valves. This apparatus enabled most accurate and reliable
measurements of MLCK velocity. The results from these studies indicated that MLCK
velocity (% MLC phosphorylated/sec) is significantly greater in fetal (7.39 ± 0.53) as
compared to adult (6.56 ± 0.29) arteries. When these values are normalized to the total
MLC present in the artery segments, the results indicated that there is no significant
difference in MLCK velocity (ng MLC phosphorylated/sec) between the fetal (89.4 ±6.4)
and adult (93.2 ± 4.1) arteries. Further correction of these MLCK velocities (ng MLC
phosphorylated/sec/ng MLCK) for differences in MLCK abundance did reveal that fetal
MLCK velocity (1.52 ± 0.11) is significantly greater than adult (0.26 ± 0.01) values.
Together, these results clearly indicate that MLCK in-situ specific activity is upregulated
in fetal compared to adult arteries.
These results raise interesting possibilities regarding the factors that contribute to
these differences in MLCK in-situ specific activity. The first possibility is that
differences in intracellular calcium transients in response to stimuli may be a key factor
in explaining the differences in MLCK in-situ specific activity between fetus and adult.
In light of previously published results that intracellular calcium pools are significantly
different in fetal and adult arteries, further studies must be conducted to measure
intracellular calcium transients in response to electrical field stimulation. These
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experiments will require further modification of the existing model of rapid freeze
apparatus. Alternatively, this relationship between MLCK in-situ specific activity and
intracellular calcium concentration can be measured using buffers containing graded
calcium concentration. These studies will help in explaining if the differences in MLCK
in-situ specific activity are due to differences in intracellular calcium transients. The
second possibility that can explain the observed differences in MLCK in-situ specific
activity is availability of calmodulin. As calmodulin is necessary for activation of MLCK,
colocalization of calmodulin with MLCK is critical for its activation. Owing to the fact
that ultra structural organization of fetal and adult arteries are dramatically different, the
distribution of MLCK and calmodulin must be tested using methods like
immunohistochemistry, confocal microscopy with corresponding transmural
morphometry. These studies will reveal the role of co-factors like calmodulin in
explaining the differences in MLCK in-situ specific activity. Similar studies must also be
conducted to verify the spatial organization and distribution of MLCK and MLC in both
fetal and adult arteries.
The results from MLCK in-situ specific activity measurements lead to the third
specific aim where the maximal velocity (Vmax) and Km of MLCK in artery homogenates
was measured in both fetal and adult arteries. The results from these studies indicate that
V max (ng MLC20 phosphorylated/sec) is significantly greater in fetal (163 ± 11) compared
to adult (130 ± 9) arteries. The Km values in fetal (4.80 ± 1.20 qM) were not significantly
different than adult values (3.30 ± 098 pM). Taking these results together with MLCK insitu velocity measurements, we estimated the fractional activation of the enzyme in intact
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tissue. The results revealed that fractional activation of MLCK is about 5 fold greater in
fetal arteries compared to adult arteries.
These results also raise interesting possibilities that can be further explored.
Firstly, the significant differences in Vmax of MLCK observed can be due to presence of
MLCK isoforms. This possibility can be investigated using both RT-PCR and Western
blots. For this purpose, specific primers that can differentiate MLCK isoforms must be
developed. Similarly, for Western blots specific primary antibodies for each MLCK
isoform must be developed. This will eliminate the error in detecting MLCK isoforms,
which are less abundant and co-migrate as a single band. Secondly, the differences in
V max of MLCK can be due to presence of MLC20 isoforms. The results from our mass
spectrometry studies do reveal that fetal and adult arteries express different MLC20
isoforms. As the present Vmax measurements were conducted using a common substrate
(chicken gizzard MLC20) further studies using purified isoforms of MLC20 from both
fetal and adult arteries are necessary to elucidate the role of MLC20 isoforms in
influencing MLCK velocity. For this purpose, MLC2omust be purified from both fetal
and adult arteries and MLCK & MLC20 cross over studies must be conducted.
In conclusion, these studies are the first to offer a quantitative assessment of insitu MLCK activity in fetal and adult carotid arteries and indicate the relative extents to
which specific activity and fractional activation contribute to these differences. In
addition, they also reveal how the expression of MLCK and MLC abundances influence
the overall activity of the enzyme. Together, these studies support our core hypothesis
that age related differences in myofilament calcium sensitivity involve upregulation of
MLCK activity.

95

Future studies on the contribution of other thick and thin filament regulatory
proteins in age related difference in myofilament calcium sensitivity is an interesting and
intriguing area that needs to be explored. There is already enough evidence in the
literature that multiple signaling pathways regulate myosin light chain phosphatase
activity and that it plays a key role in thick filament reactivity. However, the effect of
age-related changes on myosin light chain phosphatase activity and its impact on
myofilament calcium sensitivity needs to be investigated. Similar studies on thin filament
regulatory proteins like caldesmon, HSP27 & HSP20 is an other exciting area of research
that needs to be explored. Together, all these studies will help in establishing the
significance of myofilament calcium sensitivity in regulating the overall contractile
function of vascular smooth muscle. This in turn can provide a solid basis for developing
new strategies based on myofilament calcium sensitivity for phannacological
management of premature babies with cerebrovascular and cardiovascular instabilities.
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